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Aging of transgenic mice that overexpress the London mutant of
amyloid precursor protein (APP/V717I) (Moechars et al., 1999a)
was now demonstrated not to affect the normalized levels of a-
or b-cleaved secreted APP nor of the b-C-terminal stubs. This
indicated that aging did not markedly disturb either a- or
b-secretase cleavage of APP and failed to explain the origin of
the massive amounts of amyloid peptides Ab40 and Ab42, sol-
uble and precipitated as amyloid plaques in the brain of old
APP/V717I transgenic mice. We tested the hypothesis that aging
acted on presenilin1 (PS1) to affect g-secretase-mediated pro-
duction of amyloid peptides by comparing aged APP/V717I
transgenic mice to double transgenic mice coexpressing human
PS1 and APP/V717I. In double transgenic mice with mutant
(A246E) but not wild-type human PS1, brain amyloid peptide
levels increased and resulted in amyloid plaques when the mice
were only 6–9 months old, much earlier than in APP/V717I trans-
genic mice (12–15 months old). Mutant PS1 increased mainly
brain Ab42 levels, whereas in aged APP/V717I transgenic mice,
both Ab42 and Ab40 increased. This resulted in a dramatic
difference in the Ab42/Ab40 ratio of precipitated or plaque-
associated amyloid peptides, i.e., 3.11 6 0.22 in double APP/
V717I 3 PS1/A246E transgenic mice compared with 0.43 6 0.07
in aged APP/V717I transgenic mice, and demonstrated a clear
difference between the effect of aging and the effect of the
insertion of a mutant PS1 transgene. In conclusion, we demon-
strate that aging did not favor amyloidogenic over nonamyloido-
genic processing of APP, nor did it exert a mutant PS1-like effect
on g-secretase. Therefore, the data are interpreted to suggest
that parenchymal and vascular accumulation of amyloid in aging
brain resulted from failure to clear the amyloid peptides rather
than from increased production.
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Amyloid peptides accumulate in parenchymal plaques and vascular
deposits that constitute the major postmortem pathological hall-
mark of Alzheimer’s disease (AD). Clinical mutations in the genes
coding for amyloid precursor protein (APP) or presenilins (PS1
and PS2) cause early-onset familial AD (EOFAD) (Hardy, 1997;
Selkoe, 1998) and affect the proteolytic processing of APP directly
to yield more amyloidogenic peptides. However, EOFAD accounts
for only a minority of AD cases, while aging remains the most
prevailing risk factor for AD. The effect of the mutations on the
processing of APP and on amyloid peptide formation has been
extensively studied in cells and models, including transgenic mice.
The effects of aging remain, however, less well explored.
Different transgenic mice that overexpress wild-type (wt) or
mutant (Mut) APP, PS1, or PS2 have been generated and some
recapitulate the amyloid aspects of AD pathology very well, al-
though lacking neurofibrillary tangles. In principle, these models
allow analysis of the effect of aging on APP processing and its role
in amyloid peptide accumulation and deposition. Double transgenic
mice that coexpress APP and presenilin demonstrated that PS1
mutants essentially increase production of Ab42 (Borchelt et al.,
1996; Duff et al., 1996; Citron et al., 1997) and cause early devel-
opment of amyloid plaques as in EOFAD (Borchelt et al., 1997;
Holcomb et al., 1998) as originally observed in cell biological
models (for review, see Selkoe, 1998).
Previously, we have generated and characterized transgenic mice
that overexpress human APP in their central neurons, causing early
behavioral and phenotypic changes, including cognitive impair-
ment with decreased long-term potentiation (Moechars et al., 1996,
1998a,b, 1999a,b). For further studies, we have selected the trans-
genic mouse line that overexpressed the “London” mutant of APP
(APP/V717I) (for review, see Hardy, 1997) because these develop
later in life abundant amyloid plaques in brain parenchyma
(Moechars et al., 1999a), as well as vascular deposits (Van Dorpe
et al., 2000).
In the current study, we have biochemically analyzed the effect of
aging on the pathologically relevant derivatives of APP in the brain
of APP/V717I transgenic mice. Increase in the soluble and precip-
itated amyloid peptides Ab40 and Ab42 and in the Ab42/Ab40
ratio was marked between the ages of 12 and 15 months. Aging did
not, however, alter the normalized levels of either a- or
b-secretase-cleaved APP (APPsa and APPsb) nor those of the
C-terminal “stubs” resulting from b-cleavage of APP (b-C stubs).
This excluded a major alteration in relative a- and b-secretase
cleavage of APP as the cause of amyloid accumulation in aging
brain.
Because g-secretase is controlled by or identical to PS1 (De
Strooper et al., 1998; Wolfe et al., 1999; Kimberly et al., 2000; Li et
al., 2000; Selkoe and Wolfe, 2000), we have comparatively analyzed
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the effect of aging and the effect of PS1 on amyloid peptide
accumulation. In the brain of double transgenic mice, i.e., APP/
V717I 3 PS1/A246E, we observed mainly an increase in Ab42,
resulting in earlier plaque formation, by predominant Ab42 depo-
sition. In contrast, both Ab40 and Ab42 peptides increased with
aging, and Ab40 peptides remained the most preponderant precip-
itated peptide in brain of aged APP/V717I transgenic mice. Com-
bined, this resulted in an ;10-fold difference in the Ab42/Ab40
ratio of precipitated amyloid peptides in double transgenic mice
compared with aged APP/V717I transgenic mice. Because aging
did not affect a- or b-secretase cleavage or exert a presenilin
mutant-like effect on g-secretase, we hypothesize that the accumu-
lation of amyloid was attributable to failing clearance and degra-
dation in aging brain.
MATERIALS AND METHODS
Transgenic mice. All transgenic mice used in this study were of the FVB/N
genetic background and expressed APP/V717I, PS1, or both under control
of the mouse thy1 gene promoter. The APP/V717I transgenic mice (Mo-
echars et al., 1999a) and the PS1 transgenic mice were derived essentially
as described previously (Moechars et al., 1996). Briefly, cDNA coding for
wild-type human PS1 and mutant PS1/A246E were blunted and ligated into
a XhoI site created in an adapted mouse thy1 gene (Moechars et al., 1996).
In the final construct, coding sequences and introns 2 and 3 of the mouse
thy1 gene are replaced, leaving the 59 neuron-specific control elements
intact. Linearized mini-gene constructs were microinjected into prenuclear
embryos from superovulated FVB/N females and transgenic founders
identified by Southern blotting of tail-biopt DNA by standard procedures
(Moechars et al., 1996). Transgenic strains that transmitted the transgene
in a strictly mendelian manner without integration-site effects were com-
pared, and high expressing strains were selected after Western blotting of
brain extracts. Double transgenic mice overexpressing APP/V717I and
either PS1/mutant or PS1/wt were obtained by crossbreeding of single
APP/V717I and PS1 mutant or wild-type transgenic mice.
Biochemical analysis of transgenic mouse brain. Brains of heterozygous
APP/V717I transgenic mice or of double transgenic APP/V717I 3 PS1
mice were prelevated. One hemisphere was snap-frozen in liquid nitrogen
for biochemical analysis, and the other hemisphere was fixed in 4%
paraformaldehyde for immunohistochemistry. Differential extraction was
performed to isolate fractions containing soluble proteins, membrane
proteins, and insoluble or “plaque”-associated proteins. To this end, indi-
vidual hemispheres were homogenized in 6.5 vol of ice-cold buffer con-
taining 20 mM Tris-HCl, pH 8.5, and a cocktail of proteinase inhibitors
(Boehringer Mannheim, Mannheim, Germany) using a small potter-type
mechanical homogenizer. After centrifugation (135,000 3 g for 1 hr at
4°C), a portion of the supernatant was cleared again (200,000 3 g for 2 hr
at 4°C) before analysis of soluble amyloid peptides by specified ELISA.
Figure 1. Soluble and insoluble amyloid peptides in brain of aging APP/
V717I transgenic mice. Concentrations of soluble (A) and precipitated or
plaque-associated (B) amyloid peptides, i.e., Ab40 ( gray bars) and Ab42
(black bars), were measured by specific ELISA, and results are expressed as
nanogram peptide per gram brain tissue. The ratio of the concentrations,
i.e., Ab42/Ab40 of both soluble and precipitated amyloid peptides, was
calculated (A and B, right). All histograms represent the mean with SEM of
at least four transgenic mice in each age group.
Figure 2. Immunohistochemical staining
with antibody FCA18 of brain sections of
single APP/V717I transgenic mice and
double APP/V717I 3 PS1/A246E trans-
genic mice. Amyloid plaques in subiculum
of double transgenic mouse at 8 months of
age (A) and in subiculum (B) and cortex
(C) at 13 months of age. Amyloid plaques
in subiculum (D) of APP/V717I trans-
genic mouse (15 months) and in subicu-
lum (E) and cortex ( F) of APP/V717I
transgenic mouse (18 months). G is higher
magnification to illustrate the typical neu-
ritic plaques with a dense core as de-
scribed previously (Moechars et al.,
1999a; Van Dorpe et al., 2000). H is an
example of a typical thioflavine S-stained
plaque, abundantly present in the brain of
single and double transgenic mice (Van
Dorpe et al., 2000).
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The pellet from the first centrifugation was resuspended and extracted in
15 vol of ice-cold buffer containing 10 mM Tris-HCl, pH 7.6, 150 mM
sodium chloride, 2% Triton X-100, 2% Nonidet P-40, and the cocktail of
proteinase inhibitors. After centrifugation (100,000 3 g for 1 hr at 4°C) the
supernatant (“membrane” fraction) was used for analysis of membrane-
bound proteins, and the residual pellet was resuspended and extracted in
guanidinium buffer with a final concentration of 50 mM Tris and 5 M
guanidinium chloride, pH 8.0. This extract was used to measure levels of
insoluble or plaque-associated Ab40 and Ab42 levels by specified ELISA
as detailed below.
Western blotting of membrane-bound APP, APPsa, APPsb, and the b-C
stubs. Biochemical analysis of intact membrane-bound APP (APPm),
APPsa, APPsb, and the b-C stubs was essentially performed as described
previously (Moechars et al., 1999a) with minor modifications. APPm was
measured on the membrane fraction by Western blotting with monoclonal
antibody 1G5 (Athena Neurosciences, San Francisco, CA). APPsa was
measured in the soluble protein fraction by Western blotting with the
polyclonal antibody R1736, recognizing an epitope between the a- and
b-secretase cleavage sites [amino acids (aa) 595–611] (Haass et al., 1992).
APPsb was detected in the soluble protein fraction by Western blotting
with the polyclonal antibody Ab53 (Howland et al., 1995). Briefly, samples
of the fractions were treated to contain at a final concentration 2% SDS
and 1% 2-mercaptoethanol (2-ME), and the proteins were denatured by
incubation at 95°C for 10 min. After separation on polyacrylamide gels
(8% Tris-glycine; Novex, San Diego, CA), proteins were electrophoreti-
cally transferred to nitrocellulose membranes (Hybond-ECL; Amersham
Pharmacia Biotech, Little Chalfont, UK), and Western blotting was per-
formed exactly as described previously (Moechars et al., 1999a). The b-C
stubs were immunoprecipitated from the membrane fraction with the
polyclonal antibody B717 raised against the human amyloid peptide (aa
597–612) (De Strooper et al., 1995). After incubation overnight with
antiserum and protein G-Sepharose, the collected pellets were washed,
denatured, reduced, and separated on 4–12% Nu-Page gels (Novex). After
transfer to nitrocellulose membranes, b-C stubs were detected by Western
blotting with antibody WO2 (Ida et al., 1996). After incubation with
appropriate secondary antibodies, all Western blots were developed with
the ECL detection system and photographically recorded (Hyperfilm;
Amersham Pharmacia Biotech, Little Chalfont, UK). Quantitative analysis
was performed by application on each gel of at least three serial dilutions
of a standardized pooled extract treated exactly as the experimental
samples, allowing standardization and normalization between gels and
between experiments.
Densitometric scanning of films and calculation and normalization was
performed as described previously (Moechars et al., 1999a) using a flatbed
optical density scanner and dedicated software for analysis and measure-
ment (Image Master; Amersham Pharmacia Biotech, Uppsala, Sweden). In
all experiments and assays, extraction of membrane proteins from brain
was additionally verified by measuring the membrane-bound 85 kDa sub-
unit of the low density lipoprotein receptor-related protein (LRP) as an
internal control. LRP is a membrane protein unrelated to APP and also
ubiquitously expressed in brain. The specific antiserum F36/4 was raised
against a synthetic peptide representing the ultimate 12 amino acids from
its C-terminal domain.
Western blotting of nepril ysin and presenilin1. For detection of neprilysin,
proteins of the membrane protein fraction were denatured and reduced by
boiling in sample buffer containing 2% SDS and 1% 2-ME and separated
on an 8% Tris-glycine gel (Novex). Detection was done by Western
blotting with the monoclonal antibody 56C6 (Novocastra Laboratories,
Newcastle upon Tyne, UK) (Iwata et al., 2000). For detection of PS1
protein, brains were homogenized in sucrose buffer [5 mM Tris, 250 mM
sucrose, 1 mM EGTA, pH 7.4, and a cocktail of proteinase inhibitors
(Boehringer Mannheim)] with a potter homogenize and spun at 12,000 3
g at 4°C for 10 min. The supernatant was taken and further centrifuged for
30 min at 100,000 3 g at 4°C. Proteins were denatured and reduced by
boiling in sample buffer containing a final concentration of 2% SDS and
1% 2-ME separated on 4–20% Tris-glycine gels (Novex). N- and
Figure 3. Biochemical analysis of APP interme-
diates in brain of APP/V717I transgenic mice.
Brain of heterozygous APP/V717I transgenic
mice (APP) of different age groups was analyzed
for the APP intermediates, indicated in each
panel, by Western blotting with the indicated
antibodies and representatively illustrated (right
column). All the levels are expressed relative to
those in brain of the youngest APP/V717I trans-
genic mice analyzed, i.e., 3 months old. In A–D,
the primary concentrations as measured (lef t)
were normalized to the level of expression of the
membrane-bound APPm (middle). All histo-
grams represent the mean with SEM of at least
four transgenic mice in each age group. The
Western blots also illustrate serial dilutions of a
standardized pooled extract as applied on each
gel to allow normalization.
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C-terminal fragments of PS1 were detected with the polyclonal antibodies
B14/5 and B17/2, respectively (De Strooper et al., 1997).
ELISA for soluble and plaque-associated amyloid peptides. The extracted
protein fractions were applied on small reversed phase columns (C18-Sep-
pack cartridges; Waters Associates, Milford, MA) and washed with in-
creasing concentrations of acetonitrile (5, 25, and 50%) containing 0.1%
trifluoroacetic acid. The last fraction contained the amyloid peptides, was
dried in vacuum overnight, and dissolved for measurements in ELISA.
Sandwich ELISA for Ab40 and Ab42 peptides was performed using the
capture antisera CFA3340 (Barelli et al., 1997) and 21F12, respectively,
and were developed with the biotinylated monoclonal antibody 3D6 (De
Strooper et al., 1998; Vanderstichele et al., 1998). These ELISA techniques
are essentially the same tests as used for diagnostic purposes, with only
minor modifications of the initial sample preparation.
In situ hybridization. Paraffin sections (6 mm) of double (APP/V717I 3
PS1/Mut) transgenic mice and nontransgenic mice were transferred on
silanylated glass slides, dewaxed, and rehydrated through an ethanol series.
Sections were digested with proteinase K (20 mg/ml), post-fixed in 4%
paraformaldehyde, and treated with 0.25% acetic anhydride in 0.1 mol/ l
triethanolamine-HCl. Sections were hybridized overnight in 50% demon-
ized formamide, 0.3 mol/ l NaCl, 20 mmol/ l Tris-HCl, and 5 mmol/ l
EDTA, pH 8.0, with 10% dextran sulfate, 13 Denhardt’s solution, 0.5
mg/ml yeast RNA, and 10 mmol/ l dithiothreitol and supplemented with
the appropriate radiolabeled riboprobe. After stringency washes and ribo-
nuclease A treatment, sections were dehydrated and dipped in photo-
graphic emulsion (LM-1; Amersham Pharmacia Biotech, Little Chalfont,
UK) and exposed for 1 week. For synthesis of the sense and antisense PS1
RNA, a 221 bp PCR product from exon 7 of the presenilin1 gene was
cloned in a pGEM-T vector (Promega, Madison, WI). The sense and
antisense human APP RNA probes used were synthesized from a
pGEM-T vector (Promega) in which a 263 bp PCR product from the
human APP gene was cloned. The sequences of the upper and the lower
primer used in the PCR were 59-GACTCATGGTGGGCGGTGTTGT-39
and 59-CCGATGGGTAGTGAAG CAATGGTT-39, respectively. The
plasmid was linearized with either NotI or SphI and transcribed with T7
and SP6RNA polymerase, respectively, in the presence of [ 33P]UTP.
Histology and immunohistochemistry. Brain tissue was fixed overnight in
4% paraformaldehyde at 4°C, rinsed in PBS, dehydrated, embedded in
paraffin, and sectioned. Immunohistochemistry was performed on dew-
axed sections after rehydration and quenching of endogenous peroxidase
(1% hydrogen peroxide in 50% methanol, 30 min, room temperature).
Immunostaining for the amyloid peptides was performed with antibody
FCA18 (Barelli et al., 1997) after microwave treatment of the sections in 10
mM sodium citrate, pH 6, for 8 min at an output of 450 W. After incubation
for 1 hr in blocking buffer (10% goat serum in 10 mM Tris, pH 7.4, 0.15 M
NaCl, and 0.1% Triton X-100), appropriately diluted primary antibody
was applied and incubated overnight at room temperature. After rinsing
and incubation with appropriate secondary antibodies (1 hr, room tem-
perature), immune complexes were detected by incubation with diami-
nobenzidine and hydrogenperoxide (Moechars et al., 1999a). Thiofla-
vine S staining was performed on paraffin sections according to standard
protocols.
RESULTS
Brain amyloid peptides in aging APP/V717I
transgenic mice
Brain amyloid peptides Ab40 and Ab42 were measured by specified
ELISA on protein fractions, differentially extracted from brain of
APP/V717I transgenic mice to represent soluble and plaque-
associated amyloid peptides. Biochemical analysis on one hemi-
sphere was paralleled by immunohistochemistry on the other hemi-
sphere to define the extent of the pathology in the different age
groups (Moechars et al., 1999a; Van Dorpe et al., 2000).
Compared with older mice, the levels of soluble Ab40 and Ab42
were relatively low in young APP/V717I transgenic mice of 3 and
6–9 months of age, with a similar Ab42/Ab40 ratio of ,0.4 (Fig.
1A). In APP/V717I transgenic mice of 15 months of age, the
soluble amyloid peptides were increased with an order of magni-
tude compared with young mice, with the most pronounced in-
crease in Ab42 as reflected in the Ab42/Ab40 ratio of 0.67 6 0.08
(Fig. 1A). The levels of plaque peptides, operationally defined as
extracted with the chaotrope guanidinium chloride, increased ex-
ponentially in the brain of old mice (Fig. 1B), which is evidently the
biochemical equivalent of amyloid plaque deposition as detected
histochemically (Fig. 2) (Moechars et al., 1999a; Van Dorpe et al.,
2000). Again, the relative increase was most pronounced for Ab42,
whereas Ab40 remained the predominant peptide (Fig. 1B).
The data demonstrated that aging of the APP/V717I transgenic
mice recapitulated the increase in soluble amyloid peptides (Lue et
al., 1999; Teller et al., 1996), as well as the exponential increase in
precipitated amyloid peptides (Funato et al., 1998; Lue et al., 1999)
as reported in AD patients. The current data extend the findings
obtained in two other unrelated APP transgenic mice (Hsiao et al.,
1996; Johnson-Wood et al., 1997).
Brain APPm, APPsa, APPsb, and b-C stubs in aging
APP/V717I transgenic mice
To determine how aging affected the processing of APP, we mea-
sured brain levels of membrane-bound APPm of a- and b-secreted
APP (APPsa and APPsb) and the cellular b-C stubs resulting from
Figure 4. Generation and characterization
of wild-type and mutant PS1 transgenic
mice. A, Schematic representation of the
mouse thy1 gene promoter construct, with
the APP cDNA, the wild-type PS1 cDNA,
or mutant PS1 cDNA. B, Northern blotting
of total brain RNA from heterozygous PS1
transgenic mice of line PS1/Wt/7 (lane 1),
PS1/Wt/8 (lane 2), PS1/Wt/9 (lane 3), PS1/
Mut/2 (lane 4), PS1/Mut/4 (lane 5), PS1/
Mut/6 (lane 6), and a nontransgenic
FVB/N control mouse (lane 7). In trans-
genic mice, the endogenous PS1 transcript
of 2.7 kb and the transgene transcript of 4.1
kb are detected with a PS1 probe (B, right),
with the larger size attributable to the 59
and 39 untranslated regions of the thy1 gene.
Detection with a mouse thy1 gene exon 4
probe (B, left) (1.4 kb ApaI fragment) de-
tected the 1.9 kb Thy-1 mRNA and the 4.1
kb PS1 mRNA. C, In situ hybridization with
a murine PS1 probe (left panels) and a hu-
man APP probe (right panels) of brain sec-
tions of double (APP/V717I 3 PS1/Mut)
transgenic (top panels) and nontransgenic
(bottom panels) mice reveals overexpression
of presenilin1 and expression of human
APP in neurons of the hippocampus (CA1)
and cortex. D, Western blot with specified
antibodies for the C-terminal fragments
(;20 kDa) and N-terminal fragments (;30
kDa) of human PS1 (De Strooper et al.,
1997) in extracts of brain from heterozygous
wild-type PS1 (PS1/Wt/7) and homozygous
mutant PS1 (PS1/Mut/2) mice.
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b-cleavage of APPm (Selkoe, 1998). Previously, we demonstrated
that brain levels of mRNA coding for endogenous mouse APP and
for transgenic APP increased slightly with age (Moechars et al.,
1996, 1999b). This was now extended to the protein level, because
membrane-bound APP protein was found to increase with age (Fig.
3A), similar to and in close parallel with mRNA levels (Moechars
et al., 1999b). This increase was specific for APP, because the level
of the 85 kDa subunit of the LRP remained constant (Fig. 3A). LRP
was considered a suitable internal control because it is unrelated to
APP and is also a large membrane-bound protein, ubiquitously
expressed in neurons. Normalization for the difference in expres-
sion of APPm in all mice in all age groups demonstrated that
neither the secreted APPsa (Fig. 3B) and APPsb (Fig. 3C) nor the
cellular b-C stubs (Fig. 3D) were affected by aging in APP/V717I
transgenic mice.
Surprisingly then, the current data indicated that aging did not
favor b- over a-secretase cleavage of APPm to produce more of the
b-C stubs that are the obligatory precursors of the amyloid peptides
(Selkoe, 1998). This left the possibility that increased amyloid
peptide concentration and deposition was attributable to altered
g-secretase activity.
Because mutant presenilins that cause familial early-onset AD
have been proposed to affect g-secretase activity (Borchelt et al.,
1996; Duff et al., 1996; Scheuner et al., 1996; Borchelt et al., 1997;
Citron et al., 1997; Holcomb et al., 1998), we tested the hypothesis
that aging disturbed APP metabolism at the g-secretase step as
controlled by PS1.
Double transgenic mice coexpressing APP/V717I and
wild-type or mutant human PS1
Transgenic mice were generated that express human wild-type PS1
or the EOFAD mutant PS1/A246E under the transcriptional con-
trol of the mouse thy1 gene promoter, in the FVB/N mouse genetic
background, the same strategy as used to generate the APP/V717I
transgenic mice (Fig. 4A) (Moechars et al., 1999a). This warranted
coexpression of the transgenes in the same cells, namely neurons
(Fig. 4C). Three and six founders were generated for PS1 and
PS1/A246E, respectively, that stably transmitted and expressed the
transgenes (Fig. 4). Western blotting demonstrated normal and
complete processing by the presence of C- and N-terminal frag-
ments of human wild-type and mutant PS1 (Fig. 4D). For the
purpose of the current experiments, wild-type and mutant PS1
transgenic mice were crossed with the APP/V717I transgenic mice,
and double transgenic mice were identified by standard methods of
genotyping (Moechars et al., 1999a).
In double transgenic mice, overexpression of EOFAD mutant
PS1 but not human wild-type PS1 increased the Ab42/Ab40 ratio,
even in young mice, as observed by others (Borchelt et al., 1996;
Duff et al., 1996; Citron et al., 1997) (Fig. 5A). We further con-
firmed that amyloid deposition occurred at the younger age of 6–9
months in double transgenic mice with mutant PS1 compared with
12–15 months in single APP/V717I transgenic mice (Fig. 2) (Mo-
echars et al., 1999a; Van Dorpe et al., 2000).
Brain amyloid peptides and APP metabolites in aging
double transgenic mice
Double transgenic mice, i.e., APP/V717I 3 PS1/A246E, differed in
three major aspects from single APP/V717I transgenic mice when
comparatively analyzed at the ages of 6–9 and 15 months, respec-
tively (Fig. 5). First, mutant PS1 hardly affected Ab40 but consid-
erably increased the level of Ab42 when single and double trans-
genic mice of the same age were compared (Fig. 5B). The Ab42/
Ab40 ratio of soluble peptides increased from 0.30 6 0.04 to 0.96 6
0.06, respectively, in single and double transgenic mice of 6–9
months of age (Fig. 5C). Second, plaque-associated amyloid pep-
Figure 5. Comparative analysis of levels of soluble and plaque-associated
amyloid peptides in the brain of single APP/V717I and double APP/
V717I 3 PS1/A246E transgenic mice. A, Ratio of soluble Ab42/Ab40 in
brain of 6-week-old single APP/V717I (APP) and double transgenic mice,
coexpressing APP/V717I with either wild-type PS1 (APP3PS1/wt) or mu-
tant PS1 (APP3PS1/Mut). B, Levels of soluble Ab40 ( gray bars) and Ab42
(black bars) in the brain of single APP/V717I (APP) and double APP/
V717I 3 PS1/Mut (APP3PS) transgenic mice, all 6–9 months old, and
their ratio as calculated (C). D, Levels of plaque-associated Ab40 ( gray
bars) and Ab42 (black bars) in single and double transgenic mice, all 6–9
months old. E, Comparison of the Ab42/Ab40 ratio of insoluble amyloid
peptides in brain of single (APP/V717I) 15-month-old and double trans-
genic (APP/V717I3PS1/Mut) 6- to 9-month-old mice (at a comparable stage
of amyloid plaque formation). All peptides were measured by specified
ELISA and are shown as absolute levels (nanograms per gram of wet brain
tissue) (lef t) and the ratio of Ab42/Ab40 calculated (right). All histograms
represent the mean with SEM of at least three transgenic mice in each
group.
Figure 6. Western blotting for neprilysin in brain of aging
APP/V717I transgenic mice. Western blotting on membrane
proteins extracted from brain of nontransgenic FVB/N mice (A)
and APP/V717I transgenic mice (B) at the indicated ages. The
Western blots also illustrate serial dilutions of a standardized
pooled extract as applied on each gel to allow normalization.
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tides were undetectable in single APP/V717I transgenic mice at the
age of 6–9 months but were dramatically high in the brain of double
transgenic mice (Fig. 5D). Again, this is the evident biochemical
correlate of the much earlier development of amyloid plaques in
the double transgenic mice (Fig. 2). Finally, the most clear-cut
demonstration of the effect of mutant PS1 was the completely
inversed ratio of plaque Ab peptides. Ab42 was predominant in the
plaques of double transgenic mice at 6–9 months of age compared
with Ab40 in those of single APP/V717I transgenic mice at 15
months. This was most clearly marked by the exceptionally high
plaque Ab42/Ab40 ratio of 3.11 6 0.22 in double transgenic mice
compared with 0.43 6 0.07 in single APP/V717I transgenic mice
(Fig. 5E).
The marked differences in APP metabolism in the brain of the
double mutant APP 3 PS1 transgenic mice argued strongly for the
thesis that aging in the single APP/V717I transgenic mice was
mechanistically different from the effect exerted by the coexpres-
sion of the mutant PS1 transgene.
DISCUSSION
In summary, we have demonstrated that none of the known me-
tabolites of APP, i.e., APPm, APPsa, APPsb, and the b-C stubs,
correlated with the dramatic increased levels of the amyloid pep-
tides Ab40 and Ab42, soluble or precipitated as amyloid plaques, in
the brain of aging APP/V717I transgenic mice. We tested and
refuted the hypothesis that aging acted by presenilin1 as or on the
elusive g-secretase to increase production of amyloid peptides by
analyzing double transgenic mice. In this respect, it must be
stressed that, in the double transgenic mice, the pathological impact
of the combination was evident; in the brain of double transgenic
mice containing mutant PS1, but not wild-type human PS1, the
formation of amyloid plaques was already observed from 6 months
of age onward. Biochemically, we have confirmed and extended
findings in other transgenic mice (Borchelt et al., 1996, 1997; Duff
et al., 1996; Citron et al., 1997; Holcomb et al., 1998) that this was
specifically attributable to increased accumulation of Ab42 at this
earlier age. This confirmed in vivo the original defined cell biolog-
ical effect of the EOFAD PS1 mutations on APP metabolism
(Citron et al., 1998) (for review, see Selkoe, 1998)
In the absence of any indication for a major metabolic shift to the
amyloidogenic pathway, aging must be proposed to act otherwise.
The hypothesis developed during the course of this work that
clearance and degradation of amyloid peptides rather than in-
creased production was the primary problem in the brain of aging
APP/V717I transgenic mice. This coincided with renewed empha-
sis on degradation and clearance of amyloid peptides (Glabe, 2000)
after the identification of neprilysin as a potential candidate pro-
teinase (Iwata et al., 2000). Judged from Western blots, the level of
neprilysin was, however, not decreased in the brain of aged APP/
V717I transgenic mice (Fig. 6). Evidently, many other proteinases,
e.g., insulin degrading enzyme (Vekrellis et al., 2000) or proteinase
inhibitors, as well as clearance mediated by diverse carrier proteins
and receptors, could become functionally or structurally compro-
mised with aging and alone or in combination explain our obser-
vations. The great diversity of potential candidates will make it
difficult to define their functional importance and identity.
On the other hand, it is conceivable that effective removal of
amyloid peptides could involve or be mediated by many different
intracellular and extracellular proteins. The genetic and epidemi-
ological evidence for the involvement in or association with spo-
radic or late onset AD of many different genes, encoding a func-
tional wide variety of proteins, would find a plausible explanation
in this hypothesis. This also might functionally connect with the
proven involvement of apolipoprotein E, and eventually even of
a-2-macroglobulin, and their common receptor in brain, the LRP.
Other mechanisms are likely at work, and alternatively we must
consider other catabolic pathways for the amyloid peptides
(Vekrellis et al., 2000; Iwata et al., 2000; Glabe, 2000) while these
and other as yet unknown degradation and clearance mechanisms
could become compromised in aging brain. Their precise definition
and their quantitative approximation in aging brain constitutes the
most interesting and challenging sequel to our current
observations.
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